Follow
SelectImmune Pharma AB
Spotlight (Sweden)
SelectImmune Pharma is a pharmaceutical company. The company intends to develop drug candidates with focus on endogenous inflammatory agents and bacterial molecules. The products are aimed at strengthening the immune system and are mainly used for the treatment of infectious diseases, as well as chronic inflammation. The company was founded in 2017 and has the largest operations in the Nordic market.
Sector:
HEALTH CARE
Instruments & Events
The shares and options available for this company. Including past events like IPOs, direct listings and exercise periods.
Type
Ticker
ISIN
Market
SHARE
SELECT B
SE0012622785
Spotlight
Sweden (SE)
Details of share in SelectImmune Pharma AB with ticker SELECT B
Status
Active
Order book id
5A24
Amount of instruments
15 666 660
Par value
0.0500
Market cap
224 000 000.00 SEK
Currency
SEK
First trading date
26 Jun 2019
Terms
Type
Price
Pre-money valuation
Time
Files
IPO
7.50 SEK
87.5M SEK
27 May - 11 Jun 2019
IPO in SelectImmune Pharma AB
Type
Ticker
ISIN
Market
OPTION
SELECT TO 1 B
SE0012675601
Spotlight
Sweden (SE)
Details of option in SelectImmune Pharma AB with ticker SELECT TO 1 B
Status
Active
Order book id
5CFG
Amount of instruments
Market cap
Currency
SEK
First trading date
15 Jul 2019
Terms
The holder shall be entitled to subscribe for one (1) new class B share in the company for each one (1) warrant.
Type
Price
Pre-money valuation
Time
Files
Exercise
8.00 SEK
03 Sep - 17 Sep 2020
-
Option exercise terms for SELECT TO 1 B
People
Jacob Testad (tf)
CEO
Catharina Svanborg
Chairman of the board
Carl-Johan Wachtmeister
Board member
Gabriela Godaly
Board member
Helena Lomberg
Board member
Company Details
Sector
HEALTH CARE

Address
Klinikgatan 32
Zip code
222 42
City/district
Lund
Country
Sweden (SE)
Registration number
559104-6874
LEI code
549300UJSDOUNOHDHL66
First trade date
26 Jun 2019
Registration date
15 Mar 2017
Short name
SelectImmune Pharma

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More

Create Your FREE Account to stay Up To Date